-
KaloBios OTC Shares Up 80%, Leading Martin Shkreli To Tweet About His Former Company
Wednesday, March 23, 2016 - 12:40pm | 325Read More...KaloBios Pharmaceuticals Inc (OTC: KBIOQ) shares were up more than 74 percent at $7.85 Wednesday afternoon, hitting a day's high of $9. The surge in price led its former CEO, Martin Shkreli, to chime in on his former company. "$KBIOQ has same assets and a BETTER CEO than me but stock...
-
Chagas Drug Hope Lifts KaloBios Stock
Thursday, February 4, 2016 - 3:38pm | 418Read More...Shares of KaloBios Pharmctcls (OTC: KBIOQ) climbed as much as 22 percent Thursday after a WSJ report said the embattled pharma company may still get its hand on the drug used to treat Chagas disease. KaloBios, which filed for bankruptcy in December, was trying to buy the drug when its former...
-
NASDAQ: KaloBios' Bankruptcy Announcement Constitutes A 'Separate And Additional Basis' For Stock
Thursday, December 31, 2015 - 1:52pm | 145Read More...KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) disclosed on Thursday it received a new letter from the Nasdaq exchange on Wednesday. According to KaloBios, the letter from Nasdaq stated that the company's filing for bankruptcy under Chapter 11 constitutes a "separate and additional basis for delisting...
-
Martin Shkreli Tells Wall Street Journal Drug Price Hikes, Over-The-Top Persona Reasons Behind His Arrest
Monday, December 21, 2015 - 12:56pm | 219Read More...KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) confirmed in a press release Monday that Martin Shkreli will no longer continue serving as the company's CEO following his arrest. Shkreli spoke for the first time following his arrest and told The Wall Street Journal that he has been targeted by...
-
Martin Shkreli: Who's Tim Sykes?
Wednesday, November 25, 2015 - 12:19pm | 434Read More...Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) fell around 50 percent on Tuesday. Notable penny trading expert Tim Sykes told New York Post that KaloBios' stock is expected to return to being a penny stock. Martin Shkreli, KaloBios' newly appointed CEO and major stockholder...
-
KaloBios Names Controversial Martin Shkreli As Its New CEO
Friday, November 20, 2015 - 9:45am | 396Read More...Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) rose more than 400 percent on Thursday after the company announced Martin Shkreli and a group of investors acquired a majority stake in the company. KaloBios' stock jumped another 12 percent early Friday morning after the company...
-
Martin Shkreli Makes 1,080% On Penny Stock Days After Company Said It Would Shut Down
Wednesday, November 18, 2015 - 6:43pm | 267Read More...KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) is a monoclonal antibody therapeutics company that traded as a penny stock as recently as this Monday. The company now trades above the $15.00 mark on Wednesday's after-hours session after an SEC disclosure from noted biotech investor Martin Shkreli...
